• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression, an uncommon variant.具有淋巴浆细胞形态和细胞周期蛋白D1表达的浆细胞骨髓瘤,一种罕见的变异型。
Proc (Bayl Univ Med Cent). 2017 Apr;30(2):192-194. doi: 10.1080/08998280.2017.11929581.
2
Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1.在过表达细胞周期蛋白D1的骨髓瘤细胞中进行细胞周期分析及细胞周期调节基因的表达研究
Br J Haematol. 2001 Sep;114(3):591-9. doi: 10.1046/j.1365-2141.2001.02990.x.
3
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.多发性骨髓瘤中细胞周期蛋白D1/pRb/p16(INK4A)信号通路的改变
Leukemia. 2002 Sep;16(9):1844-51. doi: 10.1038/sj.leu.2402609.
4
Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.细胞周期蛋白D1的过表达不是一个特异性的分组标志物,但可能在骨髓瘤细胞中与CDC37协同作用。
Int J Oncol. 2004 Sep;25(3):579-95.
5
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.异位细胞周期蛋白D1过表达可增加多发性骨髓瘤的化疗敏感性,但不影响其细胞增殖。
Int J Oncol. 2008 Dec;33(6):1201-13.
6
Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.多发性骨髓瘤中细胞周期蛋白D1扩增与多药耐药表达相关。
Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):215-22. doi: 10.1016/j.clml.2013.07.008. Epub 2014 Jan 25.
7
Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.免疫组织化学分析鉴定出浆细胞骨髓瘤的两个细胞周期蛋白D1阳性亚群,每个亚群都与良好的生存率相关。
Am J Clin Pathol. 2006 Apr;125(4):615-24. doi: 10.1309/BDR9-59TT-4JU6-388C.
8
A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.一种新的多发性骨髓瘤细胞系MEF-1,存在细胞周期蛋白D1过表达和p53突变。
Cancer. 1999 Apr 15;85(8):1750-7. doi: 10.1002/(sici)1097-0142(19990415)85:8<1750::aid-cncr15>3.0.co;2-5.
9
Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
Med Oncol. 2004;21(1):73-80. doi: 10.1385/MO:21:1:73.
10
Requirement of ClC-3 in G0/G1 to S Phase Transition Induced by IGF-1 via ERK1/2-Cyclins Cascade in Multiple Myeloma Cells.在多发性骨髓瘤细胞中,IGF-1通过ERK1/2-细胞周期蛋白级联反应诱导G0/G1期向S期转变过程中ClC-3的需求。
Clin Lab. 2018 Jun 1;64(6):929-936. doi: 10.7754/Clin.Lab.2018.171205.

引用本文的文献

1
Lymphoplasmacytic variant of multiple myeloma.多发性骨髓瘤的淋巴浆细胞变异型
EJHaem. 2022 Apr 8;3(2):563-564. doi: 10.1002/jha2.437. eCollection 2022 May.

本文引用的文献

1
Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression.具有淋巴浆细胞形态和细胞周期蛋白D1表达的浆细胞骨髓瘤。
Blood. 2016 Mar 24;127(12):1619. doi: 10.1182/blood-2016-01-689547.
2
MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.MYD88 L265P 突变分析有助于明确结内淋巴浆细胞淋巴瘤。
Mod Pathol. 2015 Apr;28(4):564-74. doi: 10.1038/modpathol.2014.120. Epub 2014 Sep 12.
3
Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression.多发性骨髓瘤中细胞周期蛋白D1扩增与多药耐药表达相关。
Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):215-22. doi: 10.1016/j.clml.2013.07.008. Epub 2014 Jan 25.
4
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.在接受新型药物治疗的多发性骨髓瘤患者中,活检骨髓中 cyclin-D1 的表达增加可独立预测总生存期更短。
Am J Hematol. 2012 Jul;87(7):734-6. doi: 10.1002/ajh.23223. Epub 2012 May 6.
5
Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.免疫组织化学分析鉴定出浆细胞骨髓瘤的两个细胞周期蛋白D1阳性亚群,每个亚群都与良好的生存率相关。
Am J Clin Pathol. 2006 Apr;125(4):615-24. doi: 10.1309/BDR9-59TT-4JU6-388C.
6
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.细胞周期蛋白D1过表达对于接受大剂量化疗及单次或双次自体移植治疗的新诊断多发性骨髓瘤患者而言是一个有利的预后变量。
Blood. 2003 Sep 1;102(5):1588-94. doi: 10.1182/blood-2002-12-3789. Epub 2003 May 1.
7
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.多发性骨髓瘤中细胞周期蛋白D1/pRb/p16(INK4A)信号通路的改变
Leukemia. 2002 Sep;16(9):1844-51. doi: 10.1038/sj.leu.2402609.
8
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.复发性14号染色体长臂32区易位决定多发性骨髓瘤的预后,尤其是在接受强化化疗的患者中。
Blood. 2002 Sep 1;100(5):1579-83. doi: 10.1182/blood-2002-03-0749.
9
Molecular analysis of 11q13 breakpoints in multiple myeloma.
Blood. 1999 Feb 15;93(4):1330-7.

具有淋巴浆细胞形态和细胞周期蛋白D1表达的浆细胞骨髓瘤,一种罕见的变异型。

Plasma cell myeloma with lymphoplasmacytic morphology and cyclin D1 expression, an uncommon variant.

作者信息

Hale Daniel A, Krause John R

机构信息

Department of Pathology (Hale) and the Division of Hematopathology (Krause), the Charles A. Sammons Cancer Center, Dallas, Texas, and Baylor University Medical Center at Dallas.

出版信息

Proc (Bayl Univ Med Cent). 2017 Apr;30(2):192-194. doi: 10.1080/08998280.2017.11929581.

DOI:10.1080/08998280.2017.11929581
PMID:28405079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5349825/
Abstract

The genetic complexity of multiple myeloma is due in part to the accumulation of mutations, with primary and secondary events. One such secondary event is the development of a gene mutation that may result in overexpression of cyclin D1. The pathway involving cyclin D1 is intricately involved in cell cycle regulation from the G1 to S phase, and alterations may contribute to tumorigenesis. We present a case of cyclin D1-positive multiple myeloma with lymphoplasmacytic morphology and discuss potential diagnostic pitfalls and effects on prognosis.

摘要

多发性骨髓瘤的遗传复杂性部分归因于突变的积累,包括原发性和继发性事件。其中一个这样的继发性事件是基因突变的发生,这可能导致细胞周期蛋白D1的过表达。涉及细胞周期蛋白D1的通路在从G1期到S期的细胞周期调控中错综复杂地发挥作用,其改变可能有助于肿瘤发生。我们报告一例具有淋巴浆细胞形态的细胞周期蛋白D1阳性多发性骨髓瘤病例,并讨论潜在的诊断陷阱及其对预后的影响。